GLIDE方案治疗初发进展期及复发难治性结外鼻型NK/T细胞淋巴瘤的疗效评估

OBJECTIVE: To evaluate the efficacy of gemcitabine, asparaginase, ifosfamide, dexamethasone and etoposide (GLIDE) combination for patients with newly diagnosed advanced-stage or relapsed/refractory extranodal natural killer cell lymphoma (ENKL). METHODS: Fourty-two newly diagnosed advanced-stage or relapsed/refractory ENKL were enrolled from March 2010 to March 2016. Patients were treated with GLIDE for median 3 (2–6) cycles. Complete response (CR) rate, early CR (after 2 cycles) rate were evaluated after all treatment finished. Progression free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier method and multivariate by Cox proportional hazards models. RESULTS: Thirty-one (73.8%) patients achieved CR with 22 (52.4%) in early CR after 2 cycles of GLIDE, and 14 underwent autologous stem cell transplantation (ASCT) after achieved CR. One year PFS and OS were 65.6% and 82.7%, 4 year PFS and OS were 48.2% and 63.1%, respectively, with a median PFS of 30.5 months. Multivariate analysis indicated ECOG score 0–1 and ASCT after CR were independent prognostic factors for less relapse and longer survival. CONCLUSION: GLIDE is an effective regiment for newly diagnosed advanced-stage and relapsed/refractory ENKL.